James G. Moe
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$19.7MFederal grants as PI21 awards
5Patents grantedLatest Aug 13, 2024
35Papers812 citations
Federal awards and patents by year
AwardsPatents
21 awards · $19.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 16, 2026 | NIH | SBIR Phase II A 13-Week Oral Gavage Toxicity Study of OLX-07010 in Beagle Dogs Followed by a 4-Week Recovery Period | $1.5M | OLIGOMERIX INC |
| Aug 18, 2025 | NIH | SBIR Phase II A 13-Week Oral Gavage Toxicity Study of OLX-07010 in Beagle Dogs Followed by a 4-Week Recovery Period | $500K | OLIGOMERIX INC |
| Jul 19, 2024 | NIH | SBIR Phase II GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development forADRD | $1.5M | OLIGOMERIX INC |
| Aug 11, 2023 | NIH | SBIR Phase II GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development forADRD | $1.5M | OLIGOMERIX INC |
| Jul 21, 2023 | NIH | SBIR Phase II A 26-week rat toxicity study and efficacy and biomarker studies in Tau-APP Alzheimer's mouse model to support a Phase 1b clinical study | $1.4M | OLIGOMERIX INC |
| Sep 26, 2022 | NIH | SBIR Phase II A 26-week rat toxicity study and efficacy and biomarker studies in Tau-APP Alzheimer's mouse model to support a Phase 1b clinical study | $1.1M | OLIGOMERIX INC |
| Aug 19, 2022 | NIH | SBIR Phase II Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD | $160K | OLIGOMERIX INC |
| Jun 1, 2022 | NIH | SBIR Phase II Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD | $457K | OLIGOMERIX INC |
| May 20, 2021 | NIH | SBIR Phase II Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD | $1.3M | OLIGOMERIX INC |
| Sep 7, 2020 | NIH | SBIR Phase II Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD | $1.5M | OLIGOMERIX INC |
| Jul 29, 2020 | NIH | SBIR Phase II Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD | $1000K | OLIGOMERIX INC |
| May 22, 2020 | NIH | SBIR Phase II GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development for ADRD | $955K | OLIGOMERIX INC |
| Sep 26, 2019 | NIH | SBIR Phase II GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development for ADRD | $1.2M | OLIGOMERIX INC |
| Apr 26, 2019 | NIH | SBIR Phase II Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD | $1000K | OLIGOMERIX INC |
| Apr 22, 2019 | NIH | SBIR Phase II Tau oligomer platform validation using lead series candidate in htau mice | $984K | OLIGOMERIX INC |
| Apr 19, 2019 | NIH | SBIR Phase II Tau oligomer platform validation using lead series candidate in htau mice | $374K | OLIGOMERIX INC |
| Sep 20, 2018 | NIH | SBIR Phase II Tau oligomer platform validation using lead series candidate in htau mice | $999K | OLIGOMERIX INC |
| Sep 18, 2018 | NIH | SBIR Phase II Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD | $499K | OLIGOMERIX INC |
| Sep 1, 2017 | NIH | SBIR Phase I Development of an Alzheimer's disease specific antibody biomarker for a tau oligomer fragment | $302K | OLIGOMERIX INC |
| Apr 29, 2017 | NIH | SBIR Phase II Tau Oligomer Platform Validation Using Lead Series Candidate in htau Mice | $750K | OLIGOMERIX INC |
| Apr 26, 2016 | NIH | SBIR Phase II Tau Oligomer Platform Validation Using Lead Series Candidate in htau Mice | $750K | OLIGOMERIX INC |
6 patents as inventor
- US 10465001OLIGOMERIX INCNov 5, 2019
- US 10597649OLIGOMERIX INCMar 24, 2020
- US 11104710OLIGOMERIX INCAug 31, 2021
- US 12060591OLIGOMERIX INCAug 13, 2024
- US 9506051OLIGOMERIX INCNov 29, 2016
- US OLIGOMERIX INC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#5
Awards as PI#14
Patents#25
Companies
- OLIGOMERIX INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.